Early trial for Mucus-Busting lung drug halted
NCT ID NCT05292950
Summary
This early-stage study tested an inhaled drug called ARO-MUC5AC, designed to reduce harmful mucus in the lungs. It aimed to see if the drug was safe and how it worked in healthy volunteers and people with moderate-to-severe asthma or COPD. The study was terminated, meaning it was stopped early.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ASTHMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site 1
Nedlands, 6009, Australia
-
Research Site 1
Auckland, 1010, New Zealand
-
Research Site 1
Bialystok, 15-010, Poland
-
Research Site 1
Seoul, 04763, South Korea
-
Research Site 1
Barcelona, 08017, Spain
-
Research Site 1
Bangkok, 10700, Thailand
-
Research Site 1
Wythenshawe, Manchester, M23 9QZ, United Kingdom
-
Research Site 2
South Brisbane, Queensland, 4101, Australia
-
Research Site 2
Auckland, 1051, New Zealand
-
Research Site 2
Krakow, 31-455, Poland
-
Research Site 2
Jeonju, 54907, South Korea
-
Research Site 3
Oświęcim, 32-600, Poland
-
Research Site 3
Bucheon-si, Gyeonggi-do, 14647, South Korea
Conditions
Explore the condition pages connected to this study.